DelveInsight’s Schizophrenia Market Insights report includes a comprehensive understanding of current treatment practices, schizophrenia emerging drugs, market share of individual therapies, and current and forecasted schizophrenia market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

 

Key Takeaways from the Schizophrenia Market Report

• As per DelveInsight’s analysis, the schizophrenia market size was found to be USD 8.6 billion in 2021 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
• As per DelveInsight estimates, in the year 2021, the total prevalent cases of Schizophrenia were ~6.2 million cases in the 7MM. In the 7MM, the highest number of prevalent cases of schizophrenia were observed in the US.
• Leading schizophrenia companies such as Otsuka Pharmaceutical Development & Commercialization, Inc., H. Lundbeck A/S, Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Merck, SyneuRx International (Taiwan) Corp, Reviva Pharmaceuticals, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Minerva Neurosciences, BioXcel Therapeutics Inc, Teva Branded Pharmaceutical Products R&D, Inc., Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others are developing novel schizophrenia drugs that can be available in the schizophrenia market in the coming years.
• Some of the key therapies for schizophrenia treatment include Brexpiprazole, ICLEPERTIN (BI-425809), KarXT (Xanomeline-Trospium), NUPLAZID (pimavanserin), MK-5720, NaBen, Brilaroxazine (RP-5063), ULOTARONT (SEP-363856), LUVADAXISTAT (NBI 1165844/TAK 831), Roluperidone (MIN-101), BXCL501 80, TV-44749, Evenamide (NW-3509/NW-3509A), LYN-005 (risperidone, weekly), OKEDI (risperidone ISM), Emraclidine (CVL-231), and others.

 

Discover which therapies are expected to grab the major schizophrenia market share @ Schizophrenia Market Report

 

Schizophrenia Overview

Schizophrenia is a serious mental disorder that significantly impairs a person’s cognitive functions, emotional regulation, decision-making abilities, and interpersonal relationships. Its origins are multifaceted, arising from a complex interplay of genetic and environmental factors. Individuals with a family history of psychosis are at a higher risk of developing schizophrenia. Symptoms of schizophrenia can vary from person to person and typically fall into three primary categories: psychotic, negative, and cognitive.

 

Schizophrenia Epidemiology Segmentation

• Total Schizophrenia Prevalent Cases
• Total Schizophrenia Diagnosed Cases
• Schizophrenia Gender-specific Cases
• Schizophrenia Severity-specific Cases
• Schizophrenia Age-specific Treated Cases
• Schizophrenia Treated Cases

 

Download the report to understand which factors are driving schizophrenia epidemiology trends @ Schizophrenia Epidemiological Insights

 

Schizophrenia Treatment Market 

While there is no cure for schizophrenia, the primary objectives of treatment revolve around alleviating symptoms and preventing relapses. Schizophrenia necessitates ongoing treatment, even after symptom remission. A combination of medications and psychosocial therapy is typically employed to effectively manage the condition. In severe cases, hospitalization may be required. The pharmacological approach plays a pivotal role in treating schizophrenia, offering a range of mono and combination therapies. Antipsychotic medications are the foremost choice among psychotropic agents for schizophrenia treatment. In specific patient cohorts, treatment strategies may involve a combination of neuroleptics and antiepileptics.

 

Learn more about the FDA-approved drugs for schizophrenia @ Drugs for Schizophrenia Treatment

 

Schizophrenia Therapies and Companies

• Brexpiprazole: Otsuka Pharmaceutical Development & Commercialization, Inc./H. Lundbeck A/S
• ICLEPERTIN (BI-425809): Boehringer Ingelheim
• KarXT (Xanomeline-Trospium): Karuna Therapeutics
• NUPLAZID (pimavanserin): Acadia Pharmaceuticals
• MK-5720: Merck
• NaBen: SyneuRx International (Taiwan) Corp
• Brilaroxazine (RP-5063): Reviva Pharmaceuticals
• ULOTARONT (SEP-363856): Sunivion/PsychoGenics/Otsuka Pharmaceuticals
• LUVADAXISTAT (NBI 1165844/TAK 831): Neurocrine Biosciences/Takeda
• Roluperidone (MIN-101): Minerva Neurosciences
• BXCL501 80: BioXcel Therapeutics Inc
• TV-44749: Teva Branded Pharmaceutical Products R&D, Inc.
• Evenamide (NW-3509/NW-3509A): Newron Pharmaceuticals
• LYN-005 (risperidone, weekly): Lyndra Therapeutics
• OKEDI (risperidone ISM): Pharmaceuticals Laboratories
• Emraclidine (CVL-231): Cerevel Therapeutics

 

To know more about schizophrenia clinical trials, visit @ Schizophrenia Drugs

 

Schizophrenia Market Dynamics

The dynamics of schizophrenia are anticipated to change in the coming years. The rising trend in the adoption of long-acting injectable (LAI) antipsychotic medications is a primary catalyst for the expansion of the global market for schizophrenia drugs. The World Health Organization’s Comprehensive Mental Health Action Plan for the period 2013-2030 is set to contribute significantly to promoting mental health awareness and facilitating access to high-quality and affordable care for mental health disorders, aiming to reach an additional 100 million people.

 

Scope of the Schizophrenia Market Report

• Therapeutic Assessment: Schizophrenia current marketed and emerging therapies
• Schizophrenia Market Dynamics: Attribute Analysis of Emerging Schizophrenia Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

 

Discover more about schizophrenia drugs in development @ Schizophrenia Clinical Trials

 

Table of Content

1. Key Insights

2. Report Introduction

3. Schizophrenia Market Overview at a Glance

4. Executive Summary of Schizophrenia

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Key Endpoints in Schizophrenia Clinical Trials

10. Marketed Therapies

11. Emerging Therapies

12. Conjoint Analysis

13. Schizophrenia: 7 Major Market Analysis

14. Market Access and Reimbursement

15. KOL Views

16. SWOT Analysis

17. Unmet Needs

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services